Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs Ibandronate in Sub-Optimally Treated Postmenopausal Osteoporosis
NCT00936897Phase 3Completed
- Sponsor
- Amgen
- Start
- Jul 2009
- Primary completion
- Nov 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of denosumab in postmenopausal osteoporosis, sponsored by Amgen. Started Jul 2009; status: completed.
02
Drugs
denosumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00936897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00936897.